Denali Therapeutics Inc. — Director's Dealing 2021

May 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-05-04

Reporting Person: Schuth Alexander O. (COO and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-04	Common Stock	S	5998	$55.091	Disposed	515584	Indirect
2021-05-04	Common Stock	S	3557	$55.915	Disposed	512027	Indirect
2021-05-04	Common Stock	S	445	$57.39	Disposed	511582	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	91044	Direct

Footnotes

F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.

F2: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.52 to $55.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F3: The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.

F4: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.55 to $56.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F5: The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.80 to $57.54 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

F6: Includes 80,358 restricted stock units.